Cargando…

Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities

BACKGROUND: Current therapies for polycystic ovary syndrome (PCOS) are accompanied by unwanted effects. Silibinin; a flavonolignan has pleiotropic activities and favorable safety profile. PURPOSE: To investigate the efficacy of silibinin on estrous cyclicity, inflammation, oxidative stress and ovari...

Descripción completa

Detalles Bibliográficos
Autores principales: Marouf, Bushra Hassan, Ismaeel, Dana Omer, Hassan, Ali Hussein, Ali, Othman Jalal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469941/
https://www.ncbi.nlm.nih.gov/pubmed/36110507
http://dx.doi.org/10.2147/JIR.S379725
_version_ 1784788742658064384
author Marouf, Bushra Hassan
Ismaeel, Dana Omer
Hassan, Ali Hussein
Ali, Othman Jalal
author_facet Marouf, Bushra Hassan
Ismaeel, Dana Omer
Hassan, Ali Hussein
Ali, Othman Jalal
author_sort Marouf, Bushra Hassan
collection PubMed
description BACKGROUND: Current therapies for polycystic ovary syndrome (PCOS) are accompanied by unwanted effects. Silibinin; a flavonolignan has pleiotropic activities and favorable safety profile. PURPOSE: To investigate the efficacy of silibinin on estrous cyclicity, inflammation, oxidative stress and ovarian morphology in letrozole-induced PCOS in rats. METHODS: Forty-eight female Wistar albino rats were divided into 2 sets. Rats of the first set (n = 12), assigned as a negative control (NC) received only the vehicle, rats of the second set (n = 36), assigned as PCOS rats, were given letrozole 1mg/Kg orally for 21 days. On day 21, six rats from the first set and six rats from the second set were euthanized for confirmation of PCOS-induction. The remaining animals from the first set assigned as group 1, those in the second set (n = 30) were equally divided into 5 groups and treated daily for 19 days as follows: group 2 (positive control) received only the vehicle, group 3 treated with metformin 300mg/Kg orally, groups 4 and 5 treated respectively with 100 and 200 mg/Kg silibinin intraperitoneally (IP), and group 6 treated with a combination of metformin 300mg/Kg orally and silibinin 100mg/Kg IP. On day 40, blood samples were examined for luteinizing hormone (LH), testosterone (TS) and estradiol (EST) levels, the anti-inflammatory and antioxidant parameters, ovarian and uterine morphology. RESULTS: Silibinin alone or in combination with metformin was found to be effective in restoring the regularity of estrous cycle by ameliorating the abnormal alterations of LH, TS, EST, tumor necrosis factor (TNF)-α, and oxidative status and by resuming the appearance of corpora lutea and decreasing or even total absence of cystic follicles in the ovaries. CONCLUSION: Silibinin was effective in restoring estrous regularities and alleviating hormonal and histomorphological abnormalities of the ovarian and uterine tissues, this could be due to its anti-androgenic, anti-inflammatory and antioxidant properties.
format Online
Article
Text
id pubmed-9469941
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94699412022-09-14 Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities Marouf, Bushra Hassan Ismaeel, Dana Omer Hassan, Ali Hussein Ali, Othman Jalal J Inflamm Res Original Research BACKGROUND: Current therapies for polycystic ovary syndrome (PCOS) are accompanied by unwanted effects. Silibinin; a flavonolignan has pleiotropic activities and favorable safety profile. PURPOSE: To investigate the efficacy of silibinin on estrous cyclicity, inflammation, oxidative stress and ovarian morphology in letrozole-induced PCOS in rats. METHODS: Forty-eight female Wistar albino rats were divided into 2 sets. Rats of the first set (n = 12), assigned as a negative control (NC) received only the vehicle, rats of the second set (n = 36), assigned as PCOS rats, were given letrozole 1mg/Kg orally for 21 days. On day 21, six rats from the first set and six rats from the second set were euthanized for confirmation of PCOS-induction. The remaining animals from the first set assigned as group 1, those in the second set (n = 30) were equally divided into 5 groups and treated daily for 19 days as follows: group 2 (positive control) received only the vehicle, group 3 treated with metformin 300mg/Kg orally, groups 4 and 5 treated respectively with 100 and 200 mg/Kg silibinin intraperitoneally (IP), and group 6 treated with a combination of metformin 300mg/Kg orally and silibinin 100mg/Kg IP. On day 40, blood samples were examined for luteinizing hormone (LH), testosterone (TS) and estradiol (EST) levels, the anti-inflammatory and antioxidant parameters, ovarian and uterine morphology. RESULTS: Silibinin alone or in combination with metformin was found to be effective in restoring the regularity of estrous cycle by ameliorating the abnormal alterations of LH, TS, EST, tumor necrosis factor (TNF)-α, and oxidative status and by resuming the appearance of corpora lutea and decreasing or even total absence of cystic follicles in the ovaries. CONCLUSION: Silibinin was effective in restoring estrous regularities and alleviating hormonal and histomorphological abnormalities of the ovarian and uterine tissues, this could be due to its anti-androgenic, anti-inflammatory and antioxidant properties. Dove 2022-09-09 /pmc/articles/PMC9469941/ /pubmed/36110507 http://dx.doi.org/10.2147/JIR.S379725 Text en © 2022 Marouf et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Marouf, Bushra Hassan
Ismaeel, Dana Omer
Hassan, Ali Hussein
Ali, Othman Jalal
Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities
title Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities
title_full Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities
title_fullStr Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities
title_full_unstemmed Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities
title_short Therapeutic Effects of Silibinin Against Polycystic Ovary Syndrome Induced by Letrozole in Rats via Its Potential Anti-Inflammatory and Anti-Oxidant Activities
title_sort therapeutic effects of silibinin against polycystic ovary syndrome induced by letrozole in rats via its potential anti-inflammatory and anti-oxidant activities
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469941/
https://www.ncbi.nlm.nih.gov/pubmed/36110507
http://dx.doi.org/10.2147/JIR.S379725
work_keys_str_mv AT maroufbushrahassan therapeuticeffectsofsilibininagainstpolycysticovarysyndromeinducedbyletrozoleinratsviaitspotentialantiinflammatoryandantioxidantactivities
AT ismaeeldanaomer therapeuticeffectsofsilibininagainstpolycysticovarysyndromeinducedbyletrozoleinratsviaitspotentialantiinflammatoryandantioxidantactivities
AT hassanalihussein therapeuticeffectsofsilibininagainstpolycysticovarysyndromeinducedbyletrozoleinratsviaitspotentialantiinflammatoryandantioxidantactivities
AT aliothmanjalal therapeuticeffectsofsilibininagainstpolycysticovarysyndromeinducedbyletrozoleinratsviaitspotentialantiinflammatoryandantioxidantactivities